Search

Retinal vein occlusion (RVO) is one of the leading causes of permanent vision loss. In adults, central retinal vein occlusion (CRVO) occurs in 1.8% while branch retinal vein occlusion (BRVO) occurs in 0.2%. Treatment strategy and disease prognosis are determined by RVO type (ischemic/non-ischemic). Despite numerous studies and many current CRVO and BRVO treatment approaches, the management of these patients is still being debated. Intravitreal injections of steroids (triamcinolone acetate, dexamethasone) and vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, ranibizumab) were shown to be fairly effective. However, it is unclear whether anti-VEGF agents are reasonable in ischemic RVOs. Laser photocoagulation remains the only effective treatment of optic nerve head and/or retinal neovascularization. Laser photocoagulation is also indicated for the treatment of macular edema. Both threshold and sub-threshold photocoagulation may be performed. Photocoagulation performed with argon (514 nm), krypton (647 nm), or diode (810 nm) laser for macular edema provides similar results (no significant differences). The treatment may be complex and include medication therapy and/or surgery. Medication therapy includes anti-aggregant agents and antioxidants, i.e., emoxypine which may be used in acute RVO as well as in post-thrombotic retinopathy.

Purpose: To show the basic regulations of the complex retinopathy of prematurity (ROP) treatment with use of retinal pattern scanning laser coagulation and early vitrectomy.Methods: Pascal pattern scanning lasercoagulation is performed for stage 2 ROP type 2, stage 3 ROP type 2 and subclinical stageand early clinical stage of aggressive posterior ROP (S. N. Fyodorov Federal State Institution «IRTC «Eye Microsurgery» Kaluga Branchclassification). Early 3‑ports 25G vitrectomy is performed if ROP progressing 2‑4 weeks after the laser treatment.Results: In 2003‑2011 823 different interventions for infants with active ROP was performed: 737 retinal lasercoagulations, 3‑ports vitrectomy — 72, 3‑ports lensvitrectomy — 14. Treatment efficacy was 98.6 % for stage 2 and stage 3 ROP (regress of the disease occurred in 557 of 565 eyes), and 74.4 % for aggressive posterior ROP (regress of the disease occurred in 128 of 172 eyes). The total efficacy of the complex treatment was 92.9 % (regress of the disease occurred in 685 of 737 eyes).Conclusion: The basic regulations of the complex ROP treatment are early, within first 6 weeks of chronologic age, photocoagulationto delay progression of the retinal detachment and to stabilize vascularity, and early vitrectomy if ROP progressing after the lasertreatment.

Purpose: to determine efficiency of Proteflazidum in treatment of herpetic uveitis.Methods: 87 eyes of 78 patients, suffering by different forms herpetic uveitis were studied. In I (control) group (41 eyes) applied traditional treatment. In II (basic) group (46 eyes) as a part of complex therapy applied Proteflazid inside. Carrying out Immunoenzyme analysis of blood and polymerase chain reaction studies with conjunctival scrapings in dynamics of treatment herpetic cornea inflam- mation, has been allowed to estimate objectively efficiency of spent therapy and degree cure of patients.Results: the combined treatment by a preparation of Proteflazidum and Ganciclovir for eye herpetic infection promotes stabiliza- tion of infectious process at early stages with preservation and improvement of visual functions (93.5%), to lengthening of the periods of remission (957%), normalization laboratory given (97.6%) and immunological indicators (94.9%). Data of IFA, PCR and immunogram blood in the treatment of herpetic uveitis can objectively evaluate the effectiveness of the therapy and the degree of cure of patients.Conclusion: Сomplex treatment of herpetic uveitis with drug Proteflazidum is more effective than traditional treatment regimen.